17,261 trials
Bladder Cancer · Transitional Cell Cancer of the Renal Pelvis and Ureter · Urethral Cancer
Primary: Overall Objective Response — 3; 29; 39 participants
Adenocarcinoma of the Gastroesophageal Junction · Adenocarcinoma of the Stomach · Recurrent Gastric Cancer
Primary: Median Progression-free Survival (PFS) — 8.77; 8.35 months — p=0.874
Esophageal Carcinoma
Primary: Pathologic Complete Response — 55 participants
Sarcoma · Leiomyosarcoma · Malignant Fibrous
Primary: Overall Objective Response — 0; 1; 9; 1 participants
Lymphoma
Primary: Objective Response — 3; 6; 3; 2 participants
CNS Cancer · Meningioma · Intracranial Hemangiopericytoma
Primary: Overall Objective Response — 1; 0; 1; 0 participants
Acute Coronary Syndrome
Primary: Sensitivity, Specificity of Detecting Myocardial Ischemia (Reader 1) — 75.2; 67.7 % (n/N)
Lung Cancer · Non-small Cell Lung Cancer · Bronchioloalveolar Cancer
Primary: The Radiographic Response to Gefitinib — 21 participants
Cystic Fibrosis
Primary: Effect of Digitoxin on IL-8 (Interleukin 8) in Induced Sputum in Stable Cystic Fibrosis (CF) Patients. — 4.59; 4.96; 5.04; 4.94 log 10 (pg/mL) — p=>0.05
Myeloproliferative Disorder · Urothelial Carcinoma · Cancer
Primary: Evaluate the Time to Disease Progression — 6.5; 13.9 months
Multiple Myeloma and Plasma Cell Neoplasm
Primary: Disease Response — 10; 8; 10; 2 participants
Lung Cancer
Primary: Determine the Overall Objective Response — 6; 13 participants
Breast Cancer
Primary: Overall Objective Response — 0; 0; 8; 0 participants
Leukemia
Primary: Number of Participants Who Died and Had Serious Adverse Events (SAEs), Related SAEs, Adverse Events (AEs) Leading to Discontinuation, Related AEs Leading to…
Leukemia · Myelodysplastic Syndromes · Myelodysplastic/Myeloproliferative Neoplasms
Primary: Maximum Tolerated Dose — 1 mCi/kg